This was the stock's fourth consecutive day of gains.

This was the stock's third consecutive day of gains.

Inovio Pharmaceuticals (NASDAQ:INO) just reported results for the first quarter of 2024. Inovio Pharmaceuticals reported earnings per share of -$1.31. This was below the analyst estimate for EPS ...

Inovio Pharmaceuticals (INO) has been beaten down lately with too much selling pressure. While the stock has lost 11.4% over the past four weeks, there is light at the end of the tunnel as it is now ...

Investors might want to bet on Inovio Pharmaceuticals (INO), as it has been recently upgraded ... which is one of the most powerful forces impacting stock prices. The Zacks rating relies solely ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

TORONTO, March 31, 2025--Inovalis Real Estate Investment Trust (the "REIT") (TSX: INO.UN) today reported financial results for the quarter ended December 31, 2024. The audited Consolidated ...

As Inovio navigates manufacturing hurdles and prepares for a crucial Biologics License Application (BLA) submission, the firm’s stock performance and future prospects hang in the balance.